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Abstract: 27 
Background 28 
Visceral leishmaniasis (VL) treatment in HIV patients very often fails and is followed by high 29 
relapse and case-fatality rates. Hence, treatment efficacy assessment is imperative but based on 30 
invasive organ aspiration for parasite detection. In the search of a less-invasive alternative and 31 
because the host immune response is pivotal for treatment outcome in immunocompromised 32 
VL patients, we studied changes in the whole blood transcriptional profile of VL-HIV patients 33 
during treatment.  34 
Methods: 35 
Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood 36 
samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of 37 
AmBisome or AmBisome/miltefosine. Pathway analyses were combined with a machine 38 
learning approach to establish a clinically-useful 4-gene set. 39 
Findings: 40 
Distinct signatures of differentially expressed genes between D0 and D29 were identified for 41 
patients who failed treatment and were successfully treated. Pathway analyses in the latter 42 
highlighted a downregulation of genes associated with host cellular activity and immunity, and 43 
upregulation of antimicrobial peptide activity in phagolysosomes. No signs of disease 44 
remission nor pathway enrichment were observed in treatment failure patients. Next, we 45 
identified a 4-gene pre-post signature (PRSS33, IL10, SLFN14, HRH4) that could accurately 46 
discriminate treatment outcome at end of treatment (D29), displaying an average area-under-47 
the-ROC-curve of 0.95 (CI: 0.75–1.00).  48 
Interpretation: 49 
 3 
A simple blood-based signature thus holds significant promise to facilitate treatment efficacy 50 
monitoring and provide an alternative test-of-cure to guide patient management in VL-HIV 51 
patients.  52 
Funding: 53 
Project funding was provided by the AfricoLeish project, supported by the European Union 54 
Seventh Framework Programme (EU FP7). 55 
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Research in context 57 
Evidence before this study 58 
Human immunodeficiency virus (HIV) infection has been identified as a significant challenge 59 
facing visceral leishmaniasis (VL) control. VL treatment in HIV patients very often fails and 60 
results in extended treatment time followed by high relapse and case-fatality rates. In addition 61 
to limited and toxic treatment options, the treatment outcome assessment thus becomes 62 
imperative in VL-HIV patients to guide decisions on treatment extension, treatment adjustment 63 
or secondary prophylaxis initiation. However, with no alternatives to assess treatment efficacy, 64 
repeated invasive and painful aspiration from infected organs for microscopical detection of 65 
the parasite remains the only approach. Chronic patients thus undergo repeated tissue aspirates 66 
or empirical optimization of treatment regimens. Hence, the development of a less-invasive 67 
alternative to assess treatment efficacy represents an urgent and important unmet clinical need 68 
to achieve VL control. 69 
Added value of this study 70 
Our study is the first to investigate whole transcriptome changes in the severly neglected group 71 
of visceral leishmaniasis patients with a concurrent HIV infection, where the host immune 72 
response is largely uncharted but believed to be pivotal for treatment outcome. In a translational 73 
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effort, the findings were biologically interpreted and systemically reduced to a 4-gene 74 
biomarker that could accurately discriminate treatment outcome. 75 
Implications of the all the available evidence 76 
This signature holds significant promise to facilitate treatment efficacy monitoring in R&D and 77 
could provide an alternative test-of-cure to guide patient management in VL-HIV patients. 78 
 79 
Introduction 80 
Visceral leishmaniasis (VL) is a potentially fatal, yet neglected, vector-borne disseminated 81 
infection caused by protozoans of the Leishmania donovani spp. complex (1). Typical 82 
symptoms include fever spikes, substantial weight loss, splenomegaly and alterations of 83 
haematopoiesis. With a global estimate of 90,000 cases annually, Ethiopia together with Brazil, 84 
India, Kenya, Somalia, South Sudan and Sudan host more than 90% of all VL cases (2).  85 
 86 
Compared to varying cure rates of around 90-95% in VL patients, treatment of patients with a 87 
concurrent Human Immunodeficiency Virus-1 (HIV) infection (referred to herein as ‘VL-HIV 88 
patients’) in endemic regions of East-Africa, Brazil and India frequently fails. Treatment failure 89 
results in extended treatments and case-fatality rates up to 25% (3,4). This is particularly true 90 
for East Africa where antileishmanial drugs show lower efficacy rates and HIV prevalence 91 
rates of 10-20% are reported among VL patients (3). Even if apparent parasitological clearance 92 
at end of treatment and viral suppression with ART is achieved, up to 60% of VL-HIV patients 93 
will develop recurrent relapse, typically within 3-6 months after initial cure (compared to 1-94 
5% in immunocompetent VL patients) (3,5). Hence, treatment outcome assessment is 95 
imperative in VL-HIV patients to guide decisions on treatment extension, treatment adjustment 96 
or secondary prophylaxis initiation.  97 
 98 
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To date, a repeated invasive and painful aspiration for microscopical detection of the parasite 99 
from infected organs (spleen, bone marrow or lymph nodes) remains the only approach for test-100 
of-cure. Although spleen aspiration shows the highest sensitivity (6), it has a life-threatening 101 
risk of splenic haemorrhage that renders it unsuitable in patients with severe thrombocytopenia. 102 
In addition, these techniques require a great level of expertise, training of personnel and 103 
appropriate facilities where blood transfusion and management of intraabdominal bleeding is 104 
possible. Due to these reasons, chronic patients often undergo repeated tissue aspirates or 105 
empirical optimization of treatment regimens. Hence, the development of a less-invasive 106 
alternative to assess treatment efficacy represents an urgent and important unmet clinical need.  107 
 108 
Molecular techniques for parasite detection seem promising, but could be less suitable as the 109 
parasitic load in blood decreases steeply after two days of treatment and gives no information 110 
on the host’s immunological recovery (7). In immunocompromised individuals in particular, 111 
host immune response restoration has been shown to be pivotal in the efficacy of VL treatment 112 
(8). Therefore, transcriptomic signatures in peripheral blood may reflect immunological 113 
responses underpinning clearance or persistence of parasites. In recent years, gene signatures 114 
derived from blood transcriptomic profiling have shown great promise in treatment monitoring 115 
for a number of infectious diseases (9–11). With a 5-gene signature, robust prediction of 116 
treatment failure in tuberculosis patients could be achieved after 1 or 4 weeks of therapy (11). 117 
Similarly, Liu et al. identified and validated a 10-gene signature that predicted Ebola treatment 118 
outcome with an accuracy of 85% to 92% (9). Yet, previous studies were often confined to 119 
single timepoint measurements and purely statistical approaches that could be complicated by 120 
patient-to-patient variation and little biological relevance of selected genes, all jeopardizing 121 
their generalizability.  122 
 123 
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To date, two small-scale studies in VL patients described distinct expression profiles in 124 
respectively the blood and the lymph nodes before and after treatment with amphotericin B 125 
(12) or sodium stibogluconate (13). Likewise, Gardinassi et al. also defined distinct 126 
immunological signatures in the blood for active and cured L. infantum infected patients (14). 127 
Although performed in immunocompetent VL patients, these findings support the pursuit of a 128 
blood-based test-of-cure. None of the previous studies, however, sought to translate such 129 
knowledge into a clinically useful signature to guide the challenging clinical management of 130 
VL-HIV patients and facilitate the evaluation in clinical trials of urgently needed novel 131 
therapeutics. 132 
 133 
Here, to minimize the impact of heterogeneity in gene expression levels among individual VL-134 
HIV patients we studied relative changes in the gene expression profile during VL treatment. 135 
By combining biological insight with a stringent machine learning approach, we have identified 136 
a relevant and robust 4-gene blood signature that accurately determined treatment outcome in 137 
VL-HIV patients. 138 
 139 
Materials and Methods 140 
Study population and design 141 
In 2014-16, a total of 30 patients recruited at the Leishmaniasis Research and Treatment Centre 142 
(Gondar, Ethiopia) in a randomized clinical trial (RCT) on combination treatment 143 
(NCT02011958, sponsored by the Drugs for Neglected Diseases Initiative) were included in 144 
this study for additional whole blood sampling (15). In short, AmBisome monotherapy and a 145 
combination treatment of AmBisome and miltefosine were administrated. AmBisome 146 
monotherapy dosage was 40mg/kg total dose, IV infusion of 5mg/kg on day 1-5, 10, 17 and 147 
24. In the combination treatment AmBisome dosage was 30mg/kg total dose, IV infusion of 148 
 7 
5mg/kg on day 1, 3, 5, 7, 9 and 11 and miltefosine every day for 28 days (50mg if patient 149 
weight < 25kg, 100mg if patient weight is >25kg).  Treatment success was defined as absence 150 
of parasites in spleen aspirate at D29. Treatment failure at D29 was defined as presence of 151 
parasites at the D29 assessment, or no clinical response to treatment requiring rescue 152 
medication on or before D29. Treatment was extended or rescue medication was provided after 153 
D29 based on parasitological examination and clinical improvement. Once the patients had a 154 
negative parasitology result, they started a follow-up period of one year (up to D390) to assess 155 
long-term relapse-free survival and safety. Rescue therapy was also given to all patients who 156 
had a confirmed VL relapse during follow-up (for more details, see (16)). After exclusion of 2 157 
patients due to a technical error in the RNA isolation process, 28 VL-HIV patients were 158 
included in the herein described analyses (Figure 1). 159 
!160 
Ethics approval and consent to participate 161 
The study protocol was approved by the University of Gondar Institutional Review Board, the 162 
Ethiopian National Research Ethics Review Committee, the Médecins Sans Frontiers Ethics 163 
Review Board, the London School of Hygiene and Tropical Medicine Research Ethics 164 
Committee, the Antwerp University Hospital Ethics Committee, the Prince Leopold Institute 165 
of Tropical Medicine Institutional Review Board and for this specific study by the University 166 
of York Biology Ethics Committee. All patients provided informed consent and the study was 167 
carried out in accordance with international guidelines (Helsinki declaration, Good Clinical 168 
Practices and local regulations). 169 
 170 
RNA isolation and sequencing 171 
Whole blood was collected and stabilized in 2.5mL PAXgene Blood RNA tubes (PreAnalytiX 172 
GmbH, Hombrechtikon, Switzerland) and stored at -80 °C. Isolation and purification of total 173 
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RNA was performed using the PAXgene blood RNA kit (PreAnalytiX GmbH, Hombrechtikon, 174 
Switzerland) according to the manufacturer’s instructions. Next, messenger RNA was enriched 175 
by depleting ribosomal and globulin RNA (Globin-zero gold removal kit, Illumina Inc, San 176 
Diego, USA). RNA concentrations were measured with NanoDrop 1000 Spectophotometer 177 
(NanoDrop Technologies, USA) and RNA integrity using an Agilent 2100 Bioanalyzer (Nano 178 
kit, Agilent, CA, US). Subsequently, cDNA amplification, adapter ligation and indexing were 179 
carried out on 1µg of total RNA by using TruSeq stranded mRNA library preparation (Illumina 180 
Inc, San Diego, USA). Libraries were sequenced on an Illumina NextSeq500 instrument 181 
(single-end, 75bp) using 1.2 pM and 1.89% PhiX with a total of 4 runs and an average coverage 182 
of 19.3 million reads per sample. 98% of the trimmed passed-filter reads mapped against the 183 
human genome. 184 
 185 
Mechanistic approach  186 
Longitudinal and inclusive DGE analyses (FDR corrected p-value ≤ 0.05 and a ≥ 1.5 absolute 187 
fold difference) between the timepoints D0 and D29 were performed for both the treatment 188 
success and failure group, based on a paired generalized linear model with CLC Genomic 189 
Workbench software V12 (Qiagen Bioinformatics). Next, the pre-ranked feature within Gene 190 
Set Enrichment Analysis (GSEA) software v.3 (BROAD institute, California, USA) was used 191 
to determine enriched gene sets in the treatment groups. The well-defined hallmark, curated 192 
canonical and gene ontology datasets from the Molecular Signature Database (MsigDB) were 193 
used for the enrichment analyses. In addition, previously described whole blood transcription 194 
modules (BTMs) were evaluated (17,18). Gene sets were considered significant if their false 195 
discovery rate (FDR) was less than 25%. Default parameters were used with 1000 permutations 196 
and the conservative classic enrichment statistics was used for calculation of the enrichment 197 
score (ES). Gene sets that did have not a minimum of 10 genes shared with the pre-ranked gene 198 
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list were excluded from the analyses, and normalized enrichment scores were depicted.  199 
Leading edge analyses were run on the GSEA results to identify core group genes. 200 
 201 
Non-redundant biological terms were visualized in a functionally grouped network by means 202 
of the ClueGo plug-in v2.5.4 for Cytoscape v.3.7.1 (19,20). Enrichment/depletion analyses 203 
were carried out with a two-sided hypergeometric test for datasets from the EBI-UniProt GO, 204 
KEGG, REACTOME and WikiPathways databases. All genes were recognised and 45 (11.3%) 205 
were not functionally annotated. The applied kappa statistics for connectivity was kept at the 206 
default value of 0.4. GO term fusion was selected to reduce redundancy. In addition, only terms 207 
with a p-value of <0.100 were shown, as well as a GO tree interval level of 3 to 8 (medium to 208 
detailed network specificity). The autoannotate plug-in was used for cluster delineation and 209 
naming. 210 
 211 
Discriminatory approach 212 
A cross-sectional and stringent machine learning approach was designed. The count table was 213 
normalized for the ‘per sample’ sequencing depth using the DESEQ2 package in R. Genes that 214 
had a read count of zero in 80% of the samples were removed. The D29/D0 expression values 215 
were used as input for the machine learning approach to correct for patient specific expression 216 
patterns. We adopted a random forest (RF) classification with leave-one-out cross-validation. 217 
Within each cross-validation loop, a feature selection was first applied on the remaining 218 
samples, only selecting the differentially expressed genes between treatment cure and failure 219 
based on a more stringent DGE analyses (FDR corrected p-value ≤ 0.01 and a ≥ 2 absolute fold 220 
difference) to target a limited gene set of highly discriminatory genes. These DEGs were then 221 
used to construct the RF classifier. The number of trees, with a maximum depth of 4 and equal 222 
minimal number of samples in each leaf, was limited to 100. The relative importancies of the 223 
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genes in the forest decision making were stored if the left-out sample was correctly predicted. 224 
After summing the classifier importancies for each gene from every successful loop, the top 20 225 
genes were depicted. The final 4-gene RF classifier was constructed in a similar approach but, 226 
to further reduce potential overfitting, a 4-fold cross-validation was applied with a maximum 227 
tree depth of 3 and a minimal number of 3 samples in each leaf. All these analyses were carried 228 
out using the sklearn package in Python v3.7.0 (21). 229 
 230 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 231 
Predesigned PrimeTime®qPCR assays (Integrated DNA Technologies (IDT), Iowa, USA) 232 
were used for human gene expression analysis of HRH4 (Hs.PT.58.4403324), IL10 233 
(Hs.PT.58.2807216), PRSS33 (Hs.PT.58.3087623), SLFN14 (Hs.PT.58.993231) and the 234 
reference gene TBP (Hs.PT.58v.39858774) (File S2). The recommended assay with the 235 
highest algorithm score was selected for each gene. After read counts were normalized via 236 
DESEQ2, TBP was selected as reference gene based on lowest maximal deviation between 237 
samples, lowest coefficient of variation, lowest LOG2FC change, commercial availability 238 
and literature review. Previous studies have validated TBP as a reliable reference gene for 239 
qPCR (22,23) and it was detected in all study samples.  240 
Samples with sufficient left-over volume to reach an equal amount of 0.5 µg in every RNA 241 
extract were included (Figure S2). Both, cDNA synthesis with iScript cDNA synthesis Kit 242 
(BioRad laboratories, California, USA) and qPCR were performed on the QuantStudio 5 243 
real-time PCR system (Applied Biosystems, ThermoFisher, Waltham, MA USA). The 244 
PrimeTime gene expression master mix with low passive reference dye (IDT) was used. To 245 
reduce technical variation, all samples from 1 patient were run in duplicate for the four genes 246 
and reference gene on one plate simultaneously. As the efficiencies were almost all ranging 247 
between 90-110%, we used the comparative Ct-value method (ΔΔCt) for relative 248 
 11 
quantification between the timepoints. Individual LOG2FC between D29 and D0 were 249 
calculated based on CPM values or Ct-values for the RNA sequencing or RT-qPCR results, 250 
respectively. 251 
 252 
Statistical and visual analyses 253 
For patient characteristics (Table 1), continuous data was represented as medians with 254 
interquartile ranges and categorical data as numbers and frequency. Statistical significance 255 
between treatment success and failure patients was determined with the non-parametric Mann-256 
Whitney U test for continuous variables and two-sided Fisher’s exact test for categorical 257 
variables. P-values < 0.05 were considered significant. The ROC curve of the final 4-gene 258 
classifier was generated using the sklearn package in Python. The AUC, sensitivity and 259 
specificity were calculated over 1000 bootstrap iterations. For each iteration, a 4-fold cross 260 
validation was applied. Principal component analysis (PCA) scatter plots, heatmaps (Euclidean 261 
distance, complete linkage), venn diagrams and volcano plots were created with the CLC 262 
Genomic Workbench software V.12 (Qiagen Bioinformatics). Violin plots were created with 263 
Graphpad Prism v8.0.1 (GraphPad Software, San Diego, USA). 264 
 265 
Results 266 
Nested in a clinical trial, 30 VL-HIV patients underwent additional whole blood sampling. 267 
After exclusion of two patients due to technical error, a total of 28 VL-HIV patients were 268 
included in the analyses (Figure 1a). Twelve (43%) patients reached parasitological cure after 269 
1 cycle of treatment and 16 required extended or rescue treatment. At admission, half of the 270 
cases had a history of VL and 82% were on antiretroviral therapy (ART) (Table 1). In both 271 
treatment outcome groups, a similar CD4 reconstitution of around 110 cells/µL was observed 272 
after 29 days of VL treatment compared to baseline. Except for a higher percentage of viral 273 
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controllers in the treatment failure group (possibly linked to the higher number of people on 274 
ART), no significant differences in patient characteristics nor treatment regimens could be 275 
observed between the treatment success and failure group. These findings indicate that HIV-276 
related markers were not associated with VL treatment outcome and that despite a successful 277 
suppression of the viral load or CD4 T cell recovery, VL treatment failure still occurred and 278 
that vice versa, non-controlled HIV patients were able to clear the infection.  279 
 280 
 281 
 282 
Table 1: Patient characteristics before and after treatment, stratified by treatment outcome 
 TOTAL 
(n=28) 
SUCCESS  
(n=12, 43%) 
FAILURE  
(n=16, 57%) 
p-value 
Demographic characteristics 
Age, median (1-99%) 34 (27-45) 33 (28-45) 34 (27-44) 0.815 
Men, n (%) 28 (100) 12 (100) 16 (100) 1.000 
Clinical characteristics at D0 
Treatment regime, n (%)    0.491 
AmBisome 9 (32.1) 3 (25) 6 (37.5)  
AmBisome + Miltefosine 19 (67.9) 9 (75) 10 (62.5)  
Primary VL, n (%) 14 (50) 5 (41.7) 9 (56.3) 0.704 
Site of parasite detection, n (%)    0.141 
Spleen (+1 to +2) 1 (4) 1 (8) 0 (0)  
 Spleen (+3 to +6) 26 (92) 11 (92) 15 (94)  
Bone marrow 1 (4) 0 (0) 1 (6)  
On ART, n (%) 23 (82.1) 8 (66.7) 15 (93.8) 0.133 
HIV viral load, n (%)    0.049 
Undetectable 8 (29) 1 (8) 7 (44)  
>20-10000 copies/mL 7 (25) 3 (25) 4 (25)  
>10000 copies/mL 13 (46) 8 (67) 5 (31)  
CD4 count, median (1-99%) 47 (11-159) 44.5 (11-159) 61.5 (15-152) 0.516 
Concomitant diseases, n (%) 23 (82.1) 10 (83.3) 13 (81.3) 1.000 
Platelet count (x103/µl), median (1-99%) 100 (47-195) 116 (47-181) 98 (55-195) 0.693 
Clinical characteristics at D29     
Site of parasite detection, n (%)    NA 
Spleen (+1 to +2) 6 (21) NA 6 (37.5)  
 Spleen (+3 to +6) 6 (21) NA 6 (37,5)  
Bone marrow 4 (14) NA 4 (25)  
CD4 count, median (1-99%) 155 (20-341) 153 (20-285) 171 (42-341) 0.807 
Platelet count (x103/µl), median (1-99%) 221 (87-701) 206 (115-464) 235 (87-701) 0.710 
VL: visceral leishmaniasis, ART; antiretroviral therapy, HIV: human immunodeficiency virus, D: day of 
treatment, NA: not applicable 
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 283 
Figure 1: Flow charts of study participants and study design. (a) Flow chart of inclusion and stratification by 284 
treatment outcomes of study participants (b) Lay-out of the study design and generation of 4-gene signature. 285 
LTFU: lost to follow-up, D: Day of treatment, VL-HIV: visceral leishmaniasis-HIV co-infection, DGE: 286 
differential gene expression. 287 
 288 
Distinct gene expression changes in treatment success and failure patients 289 
We first used principal component analysis (PCA) to reduce the dimensionality of the data and 290 
determine whether patients could be clustered. However, after pooling all the samples, the first 291 
principal component only explained 11.9% of the total variance in the dataset and this was 292 
associated with a lower read count in one of the samples (Figure S1). 293 
 294 
To account for this high variability in transcript abundance between individual VL-HIV 295 
patients, possibly due to diverse HIV or VL histories, genetic backgrounds, nutritional status 296 
and a high presence of comorbidities (>80%, Table 1), we performed longitudinal paired 297 
analyses of intra-individual changes in gene expression levels between Day 0 (D0) and D29 298 
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(using the mechanistic approach described in Methods, Figure 1b). Differential gene 299 
expression (DGE) analyses between D0 and D29 resulted in distinct transcriptomic patterns by 300 
treatment outcome, with 397 and 194 unique DEGs for the treatment success and failure group, 301 
respectively (Figure 2a, File S1 for complete lists). Only 142 were common DEGs between 302 
the groups, of which only one (CTD-2545M3.6) encoding an uncharacterised protein was 303 
regulated in the opposite direction in the groups. An almost equal distribution of up- 304 
(n=218/397, 55%) and down- (n=179/397, 45%) regulated genes was observed during 305 
treatment success, while in the treatment failure group less genes significantly changed in 306 
expression level and their expression was mainly downregulated (n=166/194, 86%) (Figure 307 
2a). This observation was also reflected in corresponding unsupervised hierarchical clustering 308 
of the expression data (Figure 2b&c). In the treatment success group, all samples were 309 
distinctly clustered by timepoint and showed a reversed pattern at D29 (Figure 2b). In the 310 
treatment failure group, no primary clustering by timepoint could be observed with a more 311 
scattered pattern (Figure 2c), indicating no mutual delineated impact of VL treatment on host 312 
transcriptomic profile. Altogether, these results suggest that significant changes take place in 313 
the abundance of blood transcripts during successful VL treatment and that the patterns of gene 314 
expression depend on the treatment efficacy. 315 
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Figure 2: Distinct patterns of differentially expressed genes (DEGs) in treatment success and failure 318 
patients. (a) Overlap of differentially expressed genes (DEGs) between D0 and D29 for treatment success and 319 
failure patients. Venn diagram showing the number, uniqueness and directionality of the DEGs (>1.5 absolute 320 
fold change with FDR p-value <0.05 – see mechanistic approach in materials and methods) between D0 and D29 321 
for treatment success (orange, n=12) and failure cases (red, n=16) (b) Unsupervised clustering of differentially 322 
expressed genes (DEGs) in treatment success and (c) failure patients. Heat maps showing the z-scores (bottom 323 
scale) or extent of up (red) or downregulation (blue) of the DEGs (Y-axis) at D0 (green samples) and D29 (purple 324 
samples) for all individual treatment success patients (n=12) and all individual treatment failure patients (n=16). 325 
Unsupervised hierarchal clustering of the samples was applied and based on Euclidean distance and complete 326 
linkage. D: Day of treatment 327 
 328 
Functional annotation of unique gene transcripts underlying successful VL treatment 329 
To better understand the ontology and function of the 397 unique genes that showed significant 330 
alterations in their expression levels during successful VL treatment, we assessed a total of 331 
6161 published gene sets across 4 different databases for significant enrichment. In total, 77 332 
biological GO terms, 12 canonical pathways, 8 hallmark gene sets and 5 BTMs were enriched 333 
(Figure 3). Despite more than 200 upregulated genes in the treatment success cases, enriched 334 
gene sets across the four different databases showed a robust downregulation of pathways by 335 
D29, in particular those linked to cell cycle, apoptosis, proteolysis and adaptive immune 336 
response processes. The top 8 most influential genes that were part of the core enrichment 337 
group in more than 35 gene sets, included different alpha subunits of the proteasome alpha 338 
(PSMA6, PSMA2, PSMA3, PSMA4), one subunit of the proteasome 26s (PASMD14), cyclin-339 
dependent kinase 1 (CDK1), interferon-g (IFNG) and interleukin 6 (IL6). In contrast, no 340 
significant enrichments could be observed within the 194 unique DEGs from the failure group, 341 
consolidating the observation of no clear delineated impact of VL treatment on host pathways 342 
among patients with treatment failure after one month of treatment.  343 
 344 
To obtain insight in the correlations between enriched terms and define overarching pathways 345 
or processes, a functionally grouped network of enriched categories was generated that showed 346 
2 distinct clusters (Figure 4). The main cluster was downregulated and consisted of cell cycle 347 
features (green), including (stem) cell differentiation, cell division, antigen presentation, cell 348 
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proliferation and related catabolic or proteolytic processes. The second cluster was upregulated 349 
and covered features of phagolysosomal activity to kill or stop the growth of fungal and 350 
microbial organisms (purple), including G-protein coupled receptor signalling and vacuolar 351 
activity with primary (azurophilic) granules loaded with defesins and serine proteases. 352 
 353 
These findings were indicative of a clear remission of active disease in successfully treated 354 
patients. The data indicated a distinct and profound downregulation of the host cellular activity 355 
and immunity and suggested clearance of the parasite by antimicrobial peptides in 356 
phagolysosomes. 357 
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 358 
Figure 3: Enriched gene sets in the treatment success group (n=12). Normalized enrichment scores for 359 
hallmarks, GO terms and canonical pathways from the MsigDB database and previously described blood 360 
transcriptional modules are depicted in blue (downregulated) or red (upregulated) scale. The size column 361 
GO terms: biological process NES Size Hallmarks NES Size
CELL CYCLE -3,79 44 E2F TARGETS -2,92 17
CELL CYCLE PROCESS -3,72 39 G2M CHECKPOINT -2,76 17
MITOTIC CELL CYCLE -3,57 33 MYC TARGETS V1 -2,70 17
ORGANELLE FISSION -2,89 22 INTERFERON GAMMA RESPONSE -2,51 12
MITOTIC NUCLEAR DIVISION -2,86 19 TNFA SIGNALING VIA NFKB -1,74 11
NUCLEAR CHROMOSOME SEGREGATION -2,73 10 MITOTIC SPINDLE -1,69 10
SISTER CHROMATID SEGREGATION -2,71 10 MTORC1 SIGNALING -1,63 12
CHROMOSOME SEGREGATION -2,71 13 HYPOXIA 0,78 10
REGULATION OF CELL CYCLE -2,63 31 Canonical pathways NES size
CHROMOSOME ORGANIZATION -2,60 24 CELL CYCLE MITOTIC -2,60 18
CELL DIVISION -2,41 20 CELL CYCLE -2,52 20
DNA CONFORMATION CHANGE -2,37 12 DNA REPLICATION -2,45 12
REGULATION OF DNA METABOLIC PROCESS -2,34 11 MITOTIC M M G1 PHASES -2,37 11
POSITIVE REGULATION OF CELL DEATH -2,34 16 G1 S TRANSITION -2,14 10
NEGATIVE REGULATION OF TRANSPORT -2,24 11 MITOTIC G1 G1 S PHASES -2,13 10
REGULATION OF CELL CYCLE PROCESS -2,23 19 IMMUNE SYSTEM -2,02 38
REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN ... -2,20 13 CYTOKINE SIGNALING IN IMMUNE SYSTEM -1,94 14
POSITIVE REGULATION OF PROTEOLYSIS -2,18 15 METABOLISM OF AMINO ACIDS AND DERIVATIVES -1,57 11
POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC … -2,18 11 CLASS I MHC MEDIATED ANTIGEN PROCESSING… -1,47 10
REGULATION OF PROTEOLYSIS -2,16 26 ADAPTIVE IMMUNE SYSTEM -1,40 17
POSITIVE REGULATION OF CATABOLIC PROCESS -2,16 15 GPCR LIGAND BINDING 1,36 10
RESPONSE TO ALCOHOL -2,15 12 Blood transcriptional modules NES size
NEGATIVE REGULATION OF CELL CYCLE -2,11 13 M4.0 - CELL CYCLE AND TRANSCRIPTION -3,53 37
REGULATION OF CELL CYCLE PHASE TRANSITION -2,11 12 M4.1 - CELL CYCLE (I) -3,51 25
POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS -2,08 14 M4.5 - MITOTIC CELL CYCLE IN STIMULATED CD4 T … -2,07 10
NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS -2,08 20 M11 - ENRICHED IN MONOCYTES (II) -1,23 10
NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS -2,07 30 M37 - IMMUNE ACTIVATION - GENERIC CLUSTER 1,43 18
REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS -2,04 14
REGULATION OF MITOTIC CELL CYCLE -2,04 17
CELL CYCLE PHASE TRANSITION -2,03 12
REGULATION OF CATABOLIC PROCESS -2,02 24
REGULATION OF PROTEIN LOCALIZATION -1,99 22
REGULATION OF PROTEIN CATABOLIC PROCESS -1,98 19
REGULATION OF INNATE IMMUNE RESPONSE -1,97 14
REGULATION OF CELL DEATH -1,96 40
ESTABLISHMENT OF PROTEIN LOCALIZATION -1,91 15
REGULATION OF CELLULAR PROTEIN LOCALIZATION -1,89 16
NEGATIVE REGULATION OF TRANSFERASE ACTIVITY -1,88 16
REGULATION OF PROTEIN SECRETION -1,88 11
ACTIVATION OF IMMUNE RESPONSE -1,86 18
ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN -1,86 10
INNATE IMMUNE RESPONSE -1,84 23
REGULATION OF CELLULAR LOCALIZATION -1,80 31
RESPONSE TO CYTOKINE -1,80 34
POSITIVE REGULATION OF DEFENSE RESPONSE -1,77 15
ESTABLISHMENT OF LOCALIZATION IN CELL -1,77 34
PROTEIN LOCALIZATION -1,77 23
NEGATIVE REGULATION OF CELL COMMUNICATION -1,76 26
REGULATION OF TRANSFERASE ACTIVITY -1,76 40
PROTEIN CATABOLIC PROCESS -1,75 14
ANTIGEN PROCESSING AND PRESENTATION -1,73 12
POSITIVE REGULATION OF IMMUNE RESPONSE -1,72 24
CELLULAR MACROMOLECULE LOCALIZATION -1,69 22
CELLULAR MACROMOLECULAR COMPLEX ASSEMBLY -1,66 12
PROTEIN LOCALIZATION TO ORGANELLE -1,65 10
IMMUNE RESPONSE -1,63 53
REGULATION OF PROTEIN MODIFICATION PROCESS -1,63 57
NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC… -1,63 29
REGULATION OF GROWTH -1,62 22
MUSCLE ORGAN DEVELOPMENT -1,61 10
REGULATION OF T CELL PROLIFERATION -1,61 10
REGULATION OF ORGANELLE ORGANIZATION -1,61 21
PROTEOLYSIS -1,60 28
REGULATION OF CHROMOSOME ORGANIZATION -1,59 11
NEGATIVE REGULATION OF CYTOKINE PRODUCTION -1,58 12
DNA METABOLIC PROCESS -1,58 16
RESPONSE TO DRUG -1,54 17
MACROMOLECULE CATABOLIC PROCESS -1,54 22
CELLULAR RESPONSE TO STRESS -1,50 30
CELLULAR RESPONSE TO CYTOKINE STIMULUS -1,50 31
POSITIVE REGULATION OF BIOSYNTHETIC PROCESS -1,49 47
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represents the number of genes from the respective gene set found in the expression dataset. NES: normalized 362 
enrichment score 363 
 364 
 365 
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Figure 4: Functionally grouped network analyses of enriched gene sets in the treatment success group 366 
(n=12). Functionally related clusters of enriched gene sets are represented by different colours and the label of 367 
the most significant term per cluster is shown. The node size represents the term enrichment significance and the 368 
connectivity by grey lines (kappa statistics 0.4). Similar terms were fused to reduce redundancy. Bottom tables 369 
showed the directionality of significant terms and the frequency of genes from the respective terms detected in 370 
the expression dataset. The exact number of genes detected is indicated behind each bar. 371 
 372 
Gene set to accurately distinguish treatment outcome at D29 373 
After having established that the whole blood transcriptome markedly changed during the 374 
course of treatment and reflected relevant biological processes, we investigated whether this 375 
transcriptomic change could be used to accurately determine the treatment outcome at D29. To 376 
answer this question, a machine learning approach was adopted that compared D0/D29 377 
transcript abundance between treatment success and failure patients (using the discriminatory 378 
approach described in the Methods, Figure 1b). To avoid overfitting, the random forest (RF) 379 
classifiers were evaluated by leave-one-out cross-validation. In total, 70% of the constructed 380 
classifiers could correctly predict the outcome of the left-out patient. The top 20 genes with the 381 
highest summed feature importance in the tree decision making over all correctly classifying 382 
classifiers were kept and included several pseudogenes and novel transcripts (Table 2, first 383 
column). To increase the biological relevance and robustness of selected genes, these 20 genes 384 
were subsequently compared with the list of DEGs from the mechanistic approach (D0 vs D29) 385 
for overlap (Table 2). Four genes were found to be shared with the treatment success group, 386 
but none with the failure group.  387 
 388 
Next, a new RF classifier with 4-fold cross-validation was built to assess whether the 389 
combination of these 4 genes alone was able to accurately determine the treatment outcome. 390 
Bootstrapping this classifer  a 1000 times showed a mean area-under-the-ROC-curve (AUC) 391 
of 0.95 (95% CI: 0.75-1.00) - with a mean sensitivity of 84% (95% CI: 83-85) and specificity 392 
of 85% (95% CI: 83-86) - to correctly distinguish treatment failure from success cases (Figure 393 
5). We validated the findings by reverse transcription quantitative polymerase chain reaction 394 
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(RT-qPCR) and showed similar distribution patterns in log2(foldchange) (LOG2FC) changes 395 
for all 4 genes (Figure S2 and File S2). Due to the lack of follow-up samples in the 16 treatment 396 
failure patients, we could not investigate whether these patients also expressed the 4-gene 397 
signature when reaching parasitological cure after extended treatment (Figure 1a). We did, 398 
however, observe that three out of the four genes were also differentially expressed in the 13 399 
VL-HIV patients with long-term cure (cf. no relapse) at 6 months after treatment end (Figure 400 
S3a), of which eight were treatment failure cases at D29. In agreement, the four genes could 401 
not be detected in treatment failure patients at D29 with low parasite burden (1+,2+) in splenic 402 
aspirates, indicating a true cure signature that reflected disease remission after an apparent 403 
complete resolution of the parasite. 404 
 405 
With regard to long-term cure prediction, distinct patterns at D29 could be observed in gene 406 
expression levels of successfully treated patients who relapsed in the following year (n=5, 42%) 407 
and those who did not (Figure 1). Yet, our 4-gene set was mostly found in the common DEGs 408 
between long-term cured and relapsed patients, except for SLFN14, indicating little value in 409 
relapse prediction (Figure S3b). The relapsed patients overlapped for 61% with the failure 410 
group at D29, compared to only 30% with the long-term cured patients. These findings argue 411 
for the investigation of a predictive signature at D29 to predict relapse development in the next 412 
6-12 months, but patient numbers were too small to perform robust analyses. 413 
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 414 
Figure 5: Receiver operator curves (ROC) for the final random forest classifier based on the 4-gene set. 415 
(a) Showing the average AUC value of the 4-gene random forest classifier, calculated over 1000 bootstrap 416 
replicates. (b) Bar chart showing the sum of relative importancies in the classifier over 1000 bootstrap 417 
replicates. 418 
 419 
Discussion 420 
In this study, we investigated the whole blood transcriptome of 28 well-characterized Ethiopian 421 
VL-HIV patients before and after 1 month of VL treatment. We observed a distinctive pattern 422 
of disease remission in successfully cured patients and the complete lack of it in treatment 423 
failure cases. Subsequently, we identified a 4-gene signature able to discriminate treatment 424 
success at D29 with a sensitivity of 84% and specificity of 85%. Application of this signature 425 
as a low-invasive tool to assess treatment efficacy in VL-HIV patients could have significant 426 
value in guiding patient management and future R&D. 427 
 428 
Due to a possible homeostatic mechanism to control persistent infection-induced inflammation 429 
in active VL, elevated levels of the regulatory cytokine IL-10 that significantly decreased 430 
following successful treatment, have been reported in numerous animal and human studies 431 
(24,25). This marked downregulation of IL10 transcription in successfully treated patients was 432 
strongly recognized in our 4-gene signature. This is, however, in contrast with the two previous 433 
transcriptomic studies in VL patients that did not find a significant regulation of IL10 (12,13). 434 
!
P
R
S
S
33
IL
10
S
LF
N
14
H
R
H
4
0
100
200
300
400
F
e
a
tu
re
 r
e
la
ti
v
e
 i
m
p
o
rt
a
n
c
e
a                  b 
 23 
While we cannot rule out that our signature is HIV-specific, our longitudinal approach that 435 
accounts for natural variation in gene transcription between patients and the use of RNAseq 436 
instead of microarray, could have contributed to detecting these associations. Likewise, the 437 
other three genes (HRH4, PRSS33 and SLFN14) have not been reported in the previous two 438 
studies. 439 
 440 
In addition, we could not confirm the IFNG gene as the major regulator gene as reported in 441 
previous transcriptome studies of VL patients (12). Although the IFNG gene and pathways 442 
were also strongly downregulated in treated VL cases compared to active cases, we rather 443 
observed a prominent upregulation of vacuolar activity with primary (azurophilic) granules 444 
loaded with defesins and serine proteases. These genes and terms suggested an enhanced 445 
phagocytosis, neutrophil involvement and complement activation; and may reflect the 446 
proteolytic degradation responsible for parasite clearance. This process was reflected in the 4-447 
gene signature by the marked upregulation of the amidolytic activity of serine protease 33. Its 448 
predominant expression in peripheral macrophages and highest discriminatory importance in 449 
the classifier supports future studies into the role of PRSS33 in phagolyosomal degradation of 450 
Leishmania parasites.  451 
 452 
It has been postulated that the interactions of Leishmania spp. with eosinophils and mast cells 453 
influence the macrophage response to infection and the development of an adaptive immune 454 
response (26). An important mediator in this process is the histamine receptor H4, also 455 
designated as the ‘immune system histamine receptor’ due to its chemotactic properties 456 
(eosinophil migration and mast call chemotaxis) and involvement in dendritic cell activation 457 
and T-cell differentiation. Because histamines have been described to have an assisting role in 458 
in vitro clearance of Leishmania infection (26), the observed upregulation of HRH4 in 459 
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successfully treated patients could indicate clearance of parasites. Nevertheless, due to its 460 
importance in the 4-gene signature, the role of histamine, mast cells and its receptors on 461 
treatment efficacy in VL and VL-HIV patients merits further research. In particular because 462 
the H4 receptor is also being explored as a promising drug target in many chronic inflammatory 463 
disorders (27).  464 
 465 
Defects in the SLFN14 gene of the signature are associated with thrombocytopenia and 466 
excessive bleeding (28). Likewise, the platelet count is known to be altered during VL infection 467 
due to splenic sequestration and often leads to bleeding tendency. Hence, the upregulation in 468 
SLFN14 expression may reflect the described return of platelet counts to normal levels after 469 
successful cure. Yet, no clear correlation could be observed between SLFN14 expression and 470 
recovery of platelet count after therapy in our study (Figure S4). It is of note that the gene was 471 
absent in the DEG list at D210 in long-term cured patients (Figure S4). Therefore, its 472 
importance should be validated as it could have been influenced by a small group of patients 473 
with severe thrombocytopenia. Our top 20 list from the discriminatory approach consisted of 474 
many pseudogenes and novel transcripts that also warrant further research, as they are not yet 475 
fully understood but are increasingly acknowledged as key contributors to immune responses 476 
(29).! 477 
 478 
Unfortunately, we could not study differences in treatment regimens due to sample size 479 
restrictions. Therefore, it remains unknown whether the broad antiproliferative activities of 480 
miltefosine contributed to the strong predominance of the downregulated cell cycle cluster in 481 
the network analyses. This predominance is however believed to reflect a cessation of the 482 
massive proliferation and differentiation of T and B cell clonotypes during the acute adaptive 483 
immune response, as similar results were observed in studies of immunocompetent VL patients 484 
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in India and Brazil treated with amphotericin B (inciting cell wall disruption) and pentavalent 485 
antimonials (broad macromolecule inhibitor), respectively (12,14). This would indicate it is 486 
not HIV-specific nor affected by the administered drugs. Nevertheless, a true mechanistic 487 
evaluation of affected organs with single cell evaluations should be studied to assess the causal 488 
and time relationship with drug modulation and parasite reduction. It is also to be noted that 489 
we could not observe enriched gene sets in the treatment failure group but noticed a significant 490 
decline in expression of many IgG-related genes (almost 40% of all DEGs). Many of these 491 
genes were also shared at D29 with the seemingly cured patients who relapsed within the 492 
next year (35% of common DEGs). This finding could suggest the initial presence of 493 
hypergammaglobulinemia at diagnosis as a risk factor for treatment failure or relapse, and 494 
merits further research. 495 
 496 
Despite the high inter-patient variation in gene levels, we were able to construct a good 497 
classifier. We believe our methodology applied some good general practices that could be 498 
incorporated in future studies. Previous studies targeting limited transcriptomic gene sets for 499 
diagnosis or treatment outcome prediction in VL or even infectious diseases in general were 500 
mostly confined to cross-sectional comparisons at a single timepoint (9,10,30). Such studies 501 
can be complicated by patient-to-patient variation in transcript abundance and are highly 502 
dependent on the stability of the used housekeeping gene for quantification in future validation 503 
studies with RT-qPCR. Therefore, we targeted intra-individual and relative changes in 504 
transcript abundance that are likely to enhance its generalizability but require both pre and post 505 
sampling. Additionally, purely statistical approaches were often adopted to select the best 506 
discriminatory genes. Such approaches can have the inherent danger of identifying genes with 507 
little biological relevance or interpretation, jeopardizing their validation in other patient cohorts 508 
(31). Correspondingly, our top 20 list from the discriminatory approach consisted of many 509 
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pseudogenes and functionally uncharacterized transcripts. By overlaying the machine learning 510 
results with mechanistic insight analyses, we believe the 4 genes represent relevant but distinct 511 
pathways that reflect underlying biological changes during treatment. When monitoring of 512 
treatment outcome is envisioned, the specificity of these pathways or genes to Leishmania 513 
infection is also less critical, compared to signature development for diagnosis or disease 514 
development prediction.  515 
 516 
A limitation of this study is that the 4-gene set identified here is derived from data collected 517 
from a single cohort of male VL-HIV patients in a single geographic area in East Africa.  518 
Although it will be necessary to further validate this biomarker in VL-HIV patients, and to 519 
include patients from other regions/countries, this should not detract from the value of such a 520 
biomarker. Even if restricted to use in East Africa, it would still be of high interest as the burden 521 
of VL-HIV is significant in this area.  It will be of future interest to evaluate performance of 522 
this biomarker as the chemotherapeutic landscape alters, though the combination of 523 
AmBisome/miltefosine is the most effective treatment of VL-HIV patients in East Africa (15) 524 
and our data suggested that the identification of the 4-gene signature was not merely a reflection 525 
of drug choice. 526 
 527 
In the near future, a composite endpoint consisting of clinical signs, antigen detection methods 528 
and a host 4-gene biomarker could be a powerful, less-invasive tool for research and drug 529 
development (R&D) in leishmaniasis, both for immunocompetent and VL-HIV patients. In 530 
particular, future studies should assess the predictive value of the signature at earlier timepoints 531 
and evaluate the methodology required to develop a more point-of-care detection system. This 532 
may guide early case management, treatment recommendation and could facilitate early futility 533 
analyses and dose-finding studies of novel compounds. It is also to be noted that its value in 534 
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similar parasitic infections could be studied, as rather general disease remission signatures were 535 
detected. Our results also encourage future investigations in VL relapse prediction by blood-536 
based transcriptomic signatures. Yet other processes are likely to be predictive in parasite 537 
recrudescence and to be reflected in such a signature. However, the specificity of the signature 538 
to Leishmania will also become more relevant. For example, an extensively validated blood-539 
based 3-gene signature recently satisfied the WHO criteria for a non-sputum-based triage test 540 
for tuberculosis across heterogeneous culture-confirmed datasets (30).  541 
 542 
In conclusion, we have identified an easily accessible 4-gene blood signature with high 543 
discriminatory value to assess treatment efficacy at the end of treatment in VL-HIV patients. 544 
Application of this signature as a low-invasive tool to assess treatment efficacy in VL-HIV 545 
patients could have significant value in guiding patient management and future R&D. 546 
 547 
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Supplementary Materials 683 
 684 
Figure S1: Patient heterogeneity across all samples. Scatter plot representating the first 2 principal components 685 
on the axes. Each dot represents a patient sample at D0 or D29, as indicated by the node shape. Colors represent 686 
the sequencing depth or read count categories expressed per million reads. 687 
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Figure S2: RT-qPCR validation. (a) Due to the lack of left-over volume in many samples and five 689 
undetermined Ct values, relative quantification could only be performed for a subset of 12 patients (b) Violin 690 
plots of LOG2FC changes between D0 and D29 with RNA sequencing or RT-PCR for the 4-gene set. 691 
Diamonds represents data from 12 individual patients. Red diamonds indicate the subset of successfully cured 692 
patients.In particular the directionality and distribution of the individual fold changes were compared between 693 
D0 and D29, as differences in fold change values are likely to occur due to mapping, normalization and read 694 
counting strategies in a whole genome or single region assay. In cured patients (red diamonds), a similar 695 
upregulation for HRH4, PRSS33, SLFN14 and downregulation for IL10 could be observed when measured 696 
with RNA sequencing or with RT-qPCR (non-significant differences), validating the possibility to detect 697 
relative changes in our 4 genes also with RT-qPCR. P-values were calculated with the non-parametric 698 
Wilcoxon test. D: Day; RT-qPCR: reverse transcription quantitative polymerase chain reaction; Ct: cycle 699 
threshold; t. ns: non-significant. 700 
  701 
 702 
Figure S3: Overlap of differentially expressed genes (DEGs) by long-term treatment outcome. (a) Venn 703 
diagram showing the number of DEGs (>1.5 absolute fold change with FDR corrected p-value <0.05) between 704 
D0 and D29 for successfully treated patient at D29 and non-relapsed patients at D210 (cf. long-term cured). 705 
Sample was missing for 1 non-relapsed patient at D210. (b) Venn diagram showing the number of DEGs (>1.5 706 
absolute fold change with FDR corrected  p-value <0.05)  between D0 and D29 for failure (red, n=16) and 707 
successfully cured patients that did not experience a relapse in the next year (yellow, n=6) or did relapse (pink, 708 
n=5). D: day of treatment 709 
 710 
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Figure S4: Correlation between changes in SLFN14 gene expression and individual recovery in platelet 712 
count (n=28). Platelet counts are expressed in x103/µl. Linear regression lines by treatment group were added to 713 
shown directionality of the correlations. LOG2FC: log2(fold change), D: day of treatment 714 
 715 
Data File S1: List of differentially expressed genes for the treatment success group (.xlsx). 716 
Data File S2: List of differentially expressed genes for the treatment failure group (.xlsx). 717 
Data File S3: Details on the RT-qPCR validation. 718 
Gene Assay ID Ref Seq # Exon location Detects all variants 
Alternative 
available 
HRH4 Hs.PT.58.4403324 NM_021624(1) 2-3a No No 
IL10 Hs.PT.58.2807216 NM_000572 3-5 Yes  
PRSS33 Hs.PT.58.3087623 NM_152891 1-3 Yes  
SLFN14 Hs.PT.58.993231 NM_001129820 1-2 Yes  
TBP Hs.PT.58v.39858774 NM_003194(1) 1-2 No Yes 
Hs.PT.58.4403324 (HRH4) 719 
Primer 1: AAGACCCCAGTATGTTGAGTTC 720 
Primer 2: TGGCTCACTACTGACTATCTGT 721 
Probe: /5Cy5/CGATACCTGTCAGTCTCAAATGCTGTGT/3IAbRQSp/ 722 
 723 
Hs.PT.58v.39858774 (TBP) 724 
Primer 1: CAGCAACTTCCTCAATTCCTTG 725 
Primer 2: GCTGTTTAACTTCGCTTCCG 726 
Probe: /56-FAM/TGATCTTTG/ZEN/CAGTGACCCAGCATCA/3IABkFQ/ 727 
 728 
Hs.PT.58.2807216 (IL10) 729 
Primer 1: TCACTCATGGCTTTGTAGATGC 730 
Primer 2: GCGCTGTCATCGATTTCTTC 731 
Probe: /56-FAM/AGGCATTCT/ZEN/TCACCTGCTCCACG/3IABkFQ/ 732 
 733 
Hs.PT.58.3087623 (PRSS33) 734 
Primer 1: CAACGATCCGACTGGACAT 735 
Primer 2: GCCTTGAAGACAGAATGAGAGG 736 
Probe: /5HEX/AGCAGCTCC/ZEN/CAGCACCAGAA/3IABkFQ/ 737 
 738 
Hs.PT.58.993231 (SLFN14) 739 
Primer 1: TTCGTGCAGATGAAGCTGAT 740 
Primer 2: GTGGTCATGATGCTGGATACTC 741 
Probe: /56-FAM/TTGGTCACAGACTACAACTCTTGCCTG/36-TAMSp/ 742 
